Skip to content

US · BBLG · BIOTECHNOLOGY

Bone Biologics Corporation (BBLG) intrinsic value and stock valuation

$0.27as of 2026-11-21 · Mkt cap 1.77M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Bone Biologics Corporation DCF and intrinsic value

InvestorsCraft values BBLG with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BBLG’s statements →

Bone Biologics Corporation Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Burlington, MA 01803 bonebiologics.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-3.11M
20112025
Free cash flow
-$-2.69M
20112025
Total equity
$5.38M
20092025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-3.23M-$-4.22M-$-9.43M-$-3.67M-$-1.1M
Net income-$-3.11M-$-4.11M-$-8.95M-$-1.48M-$-1.61M
EPSd-$-2.66M-$-2.7M-$-34.42M-$-29.6M-$-40.25M
Operating cash flow-$-2.69M-$-4.12M-$-9.56M-$-3.57M-$-1.23M
Capital expenditure$0.00-$0.00$0.00$0.00$0.00
Free cash flow-$-2.69M-$-4.12M-$-9.56M-$-3.57M-$-1.23M
Total assets$5.8M$3.86M$3.74M$8.5M$6.68M
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-5.33M-$-3.33M-$-3.03M-$-7.54M-$-6.68M
Total equity$5.38M$3.48M$2.91M$5.95M$6.58M
Cash and short-term investments$5.33M$3.33M$3.03M$7.54M$6.68M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$1.06M$2.13M$6.91M$1.58M$80K
Selling, general and administrative expenses$2.17M$2.09M$2.52M$2.09M$1.02M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$3.23M$4.22M$9.43M$3.67M$1.1M
Cost and expenses$3.23M$4.22M$9.43M$3.67M$1.1M
Interest income$120K$60K$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$730K$810K
Depreciation and amortization$0.00$4.22M$9.43M$0.00$0.00
Ebitda-$-3.11M$110K$480K-$-750K-$-810K
Operating income-$-3.23M-$-4.22M-$-9.43M-$-3.67M-$-1.1M
Total other income/expenses, net$130K$110K$480K$2.18M-$-510K
Income before tax-$-3.11M-$-4.11M-$-8.95M-$-1.48M-$-1.61M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-3.11M-$-4.11M-$-8.95M-$-1.48M-$-1.61M
Weighted average shares outstanding$1.17M$1.52M$260K$50K$40K
Weighted average diluted shares outstanding$1.17M$1.52M$260K$50K$40K
Balance sheet
20252024202320222021
Cash and short-term investments$5.33M$3.33M$3.03M$7.54M$6.68M
Net receivables$10K$0.00$330K$580K$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$5.8M$3.86M$3.74M$8.5M$6.68M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$0.00$0.00$0.00$0.00
Total assets$5.8M$3.86M$3.74M$8.5M$6.68M
Accounts payable$420K$370K$360K$100K$100K
Short-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$780K$0.00
Total current liabilities$420K$380K$830K$2.55M$100K
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$0.00$0.00$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$420K$380K$830K$2.55M$100K
Common stock$0.00$0.00$0.00$20K$10K
Retained earnings-$-88.13M-$-85.02M-$-80.91M-$-71.96M-$-70.48M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$5.38M$3.48M$2.91M$5.95M$6.58M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$0.00$0.00$0.00$0.00
Net debt-$-5.33M-$-3.33M-$-3.03M-$-7.54M-$-6.68M
Cash flow statement
20252024202320222021
Net income-$-3.11M-$-4.11M-$-8.95M-$-1.48M-$-1.61M
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$260K$190K$150K$270K$210K
Change in working capital$170K-$-150K$130K-$-170K-$-320K
Accounts receivable-$-10K$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$90K$90K$260K$790K-$-370K
Net cash provided by operating activities-$-2.69M-$-4.12M-$-9.56M-$-3.57M-$-1.23M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$4.7M$2.62M$5.04M$4.43M$6.86M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-3.21M$0.00$0.00$0.00
Net cash used for financing activities$4.7M$4.42M$5.04M$4.43M$7.9M
Net change in cash$2.01M$300K-$-4.51M$860K$6.68M
Cash at end of period$5.33M$3.33M$3.03M$7.54M$6.68M
Operating cash flow-$-2.69M-$-4.12M-$-9.56M-$-3.57M-$-1.23M
Capital expenditure$0.00-$0.00$0.00$0.00$0.00
Free cash flow-$-2.69M-$-4.12M-$-9.56M-$-3.57M-$-1.23M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Bone Biologics Corporation

        Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.

        CEO
        Jeffrey Frelick
        Employees
        2
        Beta
        0.53

        Explore

        Frequently asked questions

        What is the intrinsic value of Bone Biologics Corporation (BBLG)?

        InvestorsCraft does not currently publish an intrinsic value for BBLG. How the IC value is calculated.

        Is BBLG undervalued?

        InvestorsCraft does not publish an undervaluation signal for BBLG at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.